Stocktoria
Beta Bionics, Inc. BBNX
Beta Bionics, Inc. (BBNX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $100.3M at a -73.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.71 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.721 |
| Retained earnings / assets | -1.125 |
| EBIT / assets | -0.218 |
| Equity / liabilities | 6.992 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BBNX | Beta Bionics, Inc. | 4/9 | 6.94 | — | +53.9% |
| NPCE | NeuroPace Inc | 5/9 | -13.13 | — | +25.1% |
| KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | 5/9 | -0.94 | — | +59% |
| LUNG | Pulmonx Corp | 3/9 | -11.04 | — | +8% |
| ANIK | Anika Therapeutics, Inc. | 5/9 | 6.68 | — | -5.9% |
| OSUR | ORASURE TECHNOLOGIES INC | 2/9 | 6.76 | — | -38.1% |
| DCTH | DELCATH SYSTEMS, INC. | 6/9 | 1.26 | 165.4 | +129.1% |
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
FAQ
Is BBNX financially healthy?
Beta Bionics, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does BBNX pay a dividend?
No, Beta Bionics, Inc. does not currently pay a dividend.
How profitable is BBNX?
In FY2025, Beta Bionics, Inc. had a net margin of -73.0% and a return on equity of -25.5%.
What is the analyst price target for BBNX?
The average Wall-Street price target for Beta Bionics, Inc. is $19.18, about 10.7% above the recent price, from 11 analysts (consensus: buy).
Is BBNX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Beta Bionics, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.